Longeveron (LGVN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
November 10, 2023 7:30 AM ESTTop Line Results from CLEAR MIND Alzheimers disease Trial Affirm Safety Profile of Lomecel-B and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks
Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association
$4 Million in Equity Financing Secured in Registered Direct Offering
ELPIS II Phase 2 Trial of Lomecel-BÂ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024
Company to Hold Conference Call and Webcast Today, November... More
